Relay Therapeutics Inc.

12/03/2024 | Press release | Distributed by Public on 12/03/2024 07:00

Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.